Prucalopride Succinate Tablets (strength: 2mg, MAH: Wuhu Yangyan Pharma) developed and manufactured by Huayi has been approved for marketing by the National Medical Products Administration (NMPA). This product is also the fifth product approved in this quarter that Huayi has helped!

Prucalopride Succinate Tablets

Prucalopride is a dihydrobenzofuran formamide compound that is a selective, high-affinity 5-hydroxytryptamine (5-HT4) receptor agonist with enterokinetic activity. Prucalopride enhances peristaltic reflexes and propulsive motor patterns in gastrointestinal tract through 5-HT4 receptor activation and is a commonly used gastrointestinal prokinetic drug in clinical practice. It is a non-long-acting prokinetic agent, which can peak and take effect quickly, with high safety and good compliance.

With advanced technical expertise and production capacity, Huayi has earned the trust of its clients. We consistently adhere to strict standards and requirements to ensure compliance in the drug production process and controllability of drug quality, meeting the stringent demands of our clients. The close strategic cooperation with Wuhu Yangyan, built on shared goals and solid trust, has successfully promoted a number of products approved for marketing by the NMPA. We are looking forward to broader cooperation with Wuhu Yangyan in the future.

Huayi will continue to deepen its efforts in the pharmaceutical field, with ongoing investment in R&D and production technologies, consistently providing clients with efficient, high-quality, cost-controllable, and reliable R&D and production services, assisting more clients and realizing win-win development for both sides!